期刊文献+

内分泌联合唑来膦酸治疗晚期前列腺癌临床对照研究 被引量:2

Endocrine Joint Zoledronic Acid in Patients With Advanced Prostate Cancer : Clinical Control Study
下载PDF
导出
摘要 目的:探讨内分泌联合唑来膦酸治疗晚期前列腺癌的临床效果。方法选取我院自2011年3月~2014年3月间46例晚期前列腺癌患者作为研究对象,随机将其分成两组,对照组患者23例采用联合唑来膦酸治疗,观察组患者23例在对照组基础上增加内分泌治疗,对比两组患者的治疗效果。结果观察组患者治疗6月、12月的碱性磷酸酶(ALP)减少情况大于对照组,两组数据对比差异具有统计学意义,P〈0.05。结论在治疗晚期前列腺癌时采用内分泌联合唑来膦酸治疗效果显著。 Objective To investigate clinical effects of endocrine therapy combined with zoledronic acid in advanced prostate cancer.Methods Since our hospital between March 2011 to March 2014,46 cases of advanced prostate cancer patients as research subjects,were randomly divided into two groups of 23 patients in the control group levelendocrine therapyacid treatment was observed in the control group,23 patients based on the use of zoledronic acid treatment group,compared to the therapeutic effect of the two groups of patients.Results Patients in the observation group in June,ALP 12 month reduction in cases was significantly greater than the control group,the difference was statistically significant data comparison,P〈 0.05.Conclusion When the use of endocrine therapy for advanced prostate cancer combined zoledronic acid treatment significantly.
作者 李中学
出处 《中国卫生标准管理》 2015年第14期102-103,共2页 China Health Standard Management
关键词 前列腺癌 内分泌治疗 唑来膦酸 Prostate cancer Endocrine therapy Zoledronic acid
  • 相关文献

参考文献3

二级参考文献50

  • 1姜凤鸣,李春萍,王春喜,张宝刚.中晚期前列腺癌内分泌治疗的临床研究[J].中国老年学杂志,2006,26(8):1019-1020. 被引量:5
  • 2Peyrornaure M,Debre B,Mao K,et al.Management of prostate cancer in China:a multicenter report of 6 institutions[J].J Urol,2005,174(5):1794-1797.
  • 3Higgins GS,McLaren DB,Kerr GR,et al.Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy[J].Int J Radiat Oncol Biol Phys,2006,65(4):982.
  • 4Oh WK.The evolving role of estrogen therapy in prostate cancer[J].Clin Prostate Cancer,2002,1(2):81-89.
  • 5Labrie F,Be1anger A,Luu-The V,et al.Gonadotropin-releasing hormone agonists in the treatment of prostate cancer[J].Endoer Rev,2005,26(3):361-379.
  • 6Yri OE,Bjoro T,Fossa SD.Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer[J].Eur Urol,2006,49(1):54-58.
  • 7Weston P,Persson BE.Re:Weckermann D,Harzmann R.Hormone therapy in prostate cancer:LHRH antagonists versus LHRH analogues[J].Eur Urol,2004,46(3):279-284.
  • 8AKaza H,Hinotsu S,Usami M,et al.Combined androgen blockade with bicalutamide for advanced prostate cancer:long-term follow-up of a phase 3,double-blind,randomized study for survival[J].Cancer,2009,115(15):3437-3445.
  • 9Schellhammer PF,Davis JW.An evaluation of bicalutamide in the treatment of prostate cancerl[J].Clin Prostate Cancer,2004,2(4):213-219.
  • 10Geller J,Albert J.Comparison of prostatic cancer tissue dihydrotestoster one level sat the time of rdaple following orchieetomyo restrogen therapy[J].J Urol,1984,132(4):693-696.

共引文献32

同被引文献12

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部